Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Bioorg Med Chem Lett. 2013 Jan 1;23(1):223-7. doi: 10.1016/j.bmcl.2012.10.132. Epub 2012 Nov 9.
This letter describes the further exploration of two series of M(1) allosteric agonists, TBPB and VU0357017, previously reported from our lab. Within the TPBP scaffold, either electronic or steric perturbations to the central piperidine ring led to a loss of selective M(1) allosteric agonism and afforded pan-mAChR antagonism, which was demonstrated to be mediated via the orthosteric site. Additional SAR around a related M(1) allosteric agonist family (VU0357017) identified similar, subtle 'molecular switches' that modulated modes of pharmacology from allosteric agonism to pan-mAChR orthosteric antagonism. Therefore, all of these ligands are best classified as bi-topic ligands that possess high affinity binding at an allosteric site to engender selective M(1) activation, but all bind, at higher concentrations, to the orthosteric ACh site, leading to non-selective orthosteric site binding and mAChR antagonism.
这封信描述了我们实验室之前报道的 M(1)变构激动剂 TBPB 和 VU0357017 的两个系列的进一步探索。在 TPBP 支架内,对中央哌啶环进行电子或空间位阻修饰会导致选择性 M(1)变构激动作用丧失,并产生泛 M(1)mAChR 拮抗作用,这被证明是通过正位点介导的。在相关 M(1)变构激动剂家族(VU0357017)的周边进一步 SAR 研究确定了类似的、微妙的“分子开关”,这些开关调节了药理学模式,从变构激动作用转变为泛 M(1)mAChR 正位拮抗作用。因此,所有这些配体最好被归类为双靶配体,它们在变构位点具有高亲和力结合,从而产生选择性 M(1)激活,但在较高浓度下,所有配体都结合到正位 ACh 位点,导致非选择性正位结合和 mAChR 拮抗作用。